Xencor Receives Second Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement MONROVIA, Calif., April 4, 2012 – Xencor, Inc. announced today that the Company received a milestone payment under a technology license agreement with Boehringer Ingelheim.

Xencor Receives SBIR Phase II Grant for High Throughput Screening of Novel Computationally Derived Optimized Proteins (BW Healthwire)–June 19, 2001—Paves the Way for Improved Biopharmaceuticals and New Industrial and Agricultural Products Xencor today announced that the company has been awarded a

Xencor Receives Patent for its Proprietary Antibody Fc Optimization Technology Monrovia, Calif. – January 9, 2008 – Xencor, Inc., a company developing protein and antibody therapeutics, announced today that it received a patent from the United States Patent and Trademark Office (US 7,317,091 B1)

Xencor Receives Milestone Payment from Pfizer Under Antibody Technology License Agreement Monrovia, CA—December 16, 2009 – Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today that the Company received a milestone

MONROVIA, Calif. , April 10, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the company has received a

SEVENTH ANTIBODY DEVELOPED WITH XENCOR'S XmAb TECHNOLOGY MOVES INTO HUMAN TRIALS

Xencor Receives Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement Monrovia, CA—October 12, 2010 – Xencor, Inc. announced today that the Company received a milestone payment from Boehringer Ingelheim. The payment was triggered by the regulatory

MONROVIA, Calif. , Dec. 5, 2017 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the Company has earned a $10

MONROVIA, Calif., January 17, 2013—Xencor, Inc. today announced it has received a milestone payment from Janssen Research & Development, LLC (Janssen R&D) resulting from the exercised option for the use of Xencor's Xtend™ half-life extension technology in a therapeutic antibody.

(BW Healthwire)–October 09, 2002—Grant to Support the Rational Design of Non-immunogenic Proteins